Effectiveness of 0.02% pentahydroxyethylnaphtoquinone (hystochrome) in patients with active and fibrous stages of retinopathy of prematurity
- Authors: Petrova NI1, Rascheskov AY1, Bolgova LP1, Habibullina NM1
-
Affiliations:
- Children’s Republican Clinical Hospital of the Health Ministry of the Republic of Tatarstan, Kazan, Russia
- Issue: Vol 93, No 6 (2012)
- Pages: 978-981
- Section: Actual problems of ophthalmology
- URL: https://journals.rcsi.science/kazanmedj/article/view/2124
- DOI: https://doi.org/10.17816/KMJ2124
- ID: 2124
Cite item
Full Text
Abstract
Aim. To study the effectiveness and safety of pentahydroxyethylnaphtoquinone (Hystochrome) in patients with active and fibrous stages of retinopathy of prematurity. Methods. 281 prematurely born babies: first group - 63 patients with retinopathy of prematurity stages I-II and vast non-vascular area; second group - 201 baby with stage III retinopathy of prematurity and posterior aggressive form of retinopathy after the performed retinal laser photocoagulation; third group - 17 babies with subtotal intraocular hemorrhage - were followed up. In addition, 29 children with fibrous stage of retinopathy of prematurity were observed. Pentahydroxyethylnaphtoquinone (Hystochrome) was used as epibulbar instillations and peribulbar injections. To assess the treatment results, examination using the «RETCAM-120» system, B-scan ultrasonography using the «AVISO» scanner and visual evoked potentials examination with flash light stimulus using the «Neuro-MVP» device were performed. Results. In babies from the first group the improvement of electrophysiological parameters was observed in 20% of cases after treatment with pentahydroxyethylnaphtoquinone, compared to 4% in control group. In the second group pentahydroxyethylnaphtoquinone improved the electrophysiological parameters in 39% of cases. In the third group (17 babies with subtotal intraocular hemorrhage) the hemorrhage degradation was twice more rapid compared to controls. There was no effect from pentahydroxyethylnaphtoquinone treatment at the late stages of the disease. No adverse effects were registered. Conclusion. Pentahydroxyethylnaphtoquinone (Hystochrome) has shown good effectiveness and safety while treating patients with non-proliferative stages of retinopathy of prematurity and vitreous hemorrhage.
Full Text
##article.viewOnOriginalSite##About the authors
N I Petrova
Children’s Republican Clinical Hospital of the Health Ministry of the Republic of Tatarstan, Kazan, Russia
A Y Rascheskov
Children’s Republican Clinical Hospital of the Health Ministry of the Republic of Tatarstan, Kazan, Russia
L P Bolgova
Children’s Republican Clinical Hospital of the Health Ministry of the Republic of Tatarstan, Kazan, Russia
N M Habibullina
Children’s Republican Clinical Hospital of the Health Ministry of the Republic of Tatarstan, Kazan, Russia
References
- Сидоренко Е.И., Парамей О.В., Аксёнова И.И. Ретинопатия недоношенных // Вестн. офтальм. - 1993. - №1. - С. 31-36.
- Сидоренко Е.И., Хаценко И.Е., Асташева И.Б. Электрофизиологические методы исследования в обследовании недоношенных детей и диагностике ретинопатии недоношенных // Вестн. офтальм. - 2002. - №1. - С. 35-39.
- Катаргина Л.А., Коголева Л.В. Избранные лекции по детской офтальмологии / Под ред. В.В. Нероева. - М.: ГЭОТАР-Медиа, 2009. - С. 27-61.
- Софронова Л.Н., Дубинина Е.Е., Мушкатина О.Ф. Диагностическая ценность определения состояния антиоксидантной системы при ретинопатии недоношенных // Вопр. охраны материнства и детства. - 1991. - №1. - С. 30-34.
- American Academy of Pediatrics. Section of ophthalmology. Screening examination of premature infants for retinopathy of prematurity // Pediatrics. - 2001. - Vol. 108, N 3. - Р. 809-811.
- The STOP-ROP Multicenter Study Group. Supplemental therapeutic oxygen for prethreshold retinopathy of prematurity (STOP-ROP), a randomized, controlled trial. I. Primary outcomes // Pediatrics. - 2000. - Vol. 105. - Р. 295-310.